ArticleHemaSphere2026

Venetoclax plus azacitidine, low-dose cytarabine, aclarubicin, and G-CSF (VA-CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single-arm Phase II clinical trial.

Xiaoping Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.